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Abstract
Antiretroviral therapy (ART) can reduce HIV levels in plasma to undetectable levels, but rather little is known about the
effects of ART outside of the peripheral blood regarding persistent virus production in tissue reservoirs. Understanding the
dynamics of ART-induced reductions in viral RNA (vRNA) levels throughout the body is important for the development of
strategies to eradicate infectious HIV from patients. Essential to a successful eradication therapy is a component capable of
killing persisting HIV infected cells during ART. Therefore, we determined the in vivo efficacy of a targeted cytotoxic therapy
to kill infected cells that persist despite long-term ART. For this purpose, we first characterized the impact of ART on HIV
RNA levels in multiple organs of bone marrow-liver-thymus (BLT) humanized mice and found that antiretroviral drug
penetration and activity was sufficient to reduce, but not eliminate, HIV production in each tissue tested. For targeted
cytotoxic killing of these persistent vRNA+ cells, we treated BLT mice undergoing ART with an HIV-specific immunotoxin. We
found that compared to ART alone, this agent profoundly depleted productively infected cells systemically. These results
offer proof-of-concept that targeted cytotoxic therapies can be effective components of HIV eradication strategies.
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bi-functional proteins that combine the effector domain of a
protein toxin with the targeting specificity of an antibody or ligand
[8–13]. Soon after HIV was identified as the causative agent of
AIDS, several immunotoxins were described as potential therapeutics for HIV [8,10]. These interventions had effector domains
from plant and bacterial protein toxins and targeting moieties
against either the HIV Env glycoprotein (gp120, gp41) or cellular
markers including CD4, CD25 or CD45RO [14–21]. The
immunotoxin we chose to evaluate for in vivo efficacy herein,
3B3-PE38, combines the 3B3 scFv which targets the conserved
CD4 binding site of HIV-1 gp120 with the Pseudomonas exotoxin A
(PE38) effector domain [22].
The fact that tissue specific effects of ART on HIV persistence
are poorly understood in patients [23] meant that there was no
baseline for characterizing the systemic effects of an immunotoxin
on HIV persistence during ART. Therefore, it was essential that
we first fully characterize the systemic impact of ART on HIV
persistence cells in vivo. To do so, we sought to analyze HIV
persistence during ART in a comprehensive panel of tissues and

Introduction
ART is a lifesaving and effective means to control HIV infection
[1]. However, the persistent nature of this infection requires
lifelong adherence to daily ART dosing [2–4]. This viral
persistence, the cumulative costs of ART, adverse events
associated with long-term ART and the constant threat of
emergence of drug-resistant viral variants have led researchers to
pursue HIV eradication therapies that will result in a viral
rebound-free interruption of therapy [2–4]. Towards this goal,
‘‘kick and kill’’ HIV eradication strategies are being developed [5].
While interventions that can induce expression of latent HIV (e.g.
histone deacetylase inhibitors and protein kinase activators) will
function as the ‘‘kick’’ [2–4], it is important to note that ‘‘kill’’
strategies cannot rely on the induction of virus expression in
latently infected cells to result in cell death [6]. Therefore,
candidate ‘‘kill’’ agents, such as immunotoxins, are being
considered for incorporation into HIV eradication protocols
[7,8]. Immunotoxins are recombinant or biochemically linked
PLOS Pathogens | www.plospathogens.org
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[38]. Furthermore, the robust suppression of plasma viremia by
ART is consistent with the presence of each of the dosed
antiretrovirals in the plasma of treated BLT mice: tenofovir
(Fig. 1C), emtricitabine (Fig. 1D) and raltegravir (Fig. 1E). Such
peripheral blood analyses are readily performed in both humans
and BLT mice; however, the ability to simultaneously examine
multiple tissues throughout the course of ART is not possible in
patients. Therefore, we evaluated antiretroviral drug penetration
as well as the impact of ART on vRNA production in multiple
organs in BLT mice. We determined drug levels in the thymic
organoid, spleen, liver, lung, terminal ileum and rectum of BLT
mice. Importantly, each of the three drugs was detected in each
matrix analyzed (Fig. 1C–E). To facilitate direct comparisons of
drug levels between tissues and plasma, the data are presented as
ng/g and ng/ml, respectively [39]. Overall, the tenofovir, FTC
and RAL levels in BLT mice were ,1.6 mM, ,0.4 mM and
,0.05 mM, respectively (Fig. 1C–E). Each of these values is higher
than the EC50 for that drug in HIV-1 infected peripheral blood
mononuclear cells (TDF: 0.005 mM; FTC: 0.01 mM; and RAL:
0.001 mM) [39–41]. The extensive antiretroviral drug penetration
observed in BLT mouse organs during ART led us to examine the
systemic impact of ART on HIV production.
We used two different approaches to measure the systemic
reduction in vRNA by ART. First, we used in situ hybridization to
quantitate the number of individual cells producing vRNA in the
human thymic organoid, spleen, lymph nodes, liver, lung, terminal
ileum and rectum of HIV infected BLT mice receiving or not
receiving ART. We found that antiretroviral penetration and
activity in these tissues was sufficient to profoundly reduce the
number of cells producing vRNA in all tissues (Fig. 2). However,
consistent with the limited human tissue data available [42],
vRNA producing cells remained detectable during therapy in all
tissues analyzed (Fig. 2). We also used RT-PCR to quantitate cellassociated vRNA levels in the bone marrow, human thymic
organoid, spleen, lymph nodes, liver lung, intestines and peripheral blood cells of BLT mice given ART for 0–64 days. We
observed a rapid decline in cell-associated vRNA levels that
plateaued by Day 28 of ART in all tissues analyzed (Fig. 3A). The
longitudinal vRNA data was analyzed using two different
regression models (Lowess and cubic). The observed reductions
in cell-associated vRNA in each tissue tested indicate that ART
penetrates these tissues sufficiently to significantly reduce viremia
in a related manner in each tissue as illustrated in the plots
depicting the individual Lowess curves graphed together (Fig. 3B).
We found that a Lowess curve generated with cell-associated
vRNA data for all tissues together (Fig. 3C) is very similar to the
reduction in plasma viremia observed specifically in human
peripheral blood soon after ART initiation [36]. We also noted
significant (p,0.001) differences in each tissue, including peripheral blood, when we compared cell-associated vRNA levels from
mice in an untreated state versus those from treated mice with
vRNA levels within the plateau stage (Fig. 4). These similarities in
vRNA reduction observed between human peripheral blood and
all of the examined tissues from BLT mice during the first months
following ART initiation suggest that blood is a reasonable
surrogate for the impact of ART throughout the body.

Author Summary
Antiretroviral therapy (ART) improves the quality of life for
HIV infected individuals. However, ART is currently a
lifelong commitment because HIV persists during treatment despite being suppressed below detection. If
therapy is stopped, the HIV reappears. A concerted effort
is ongoing to develop new eradication therapies to
prevent virus rebound, but there are challenges to be
overcome. Our work is a major step forward in this process.
We measured persistent HIV throughout the body during
ART using bone marrow/liver/thymus (BLT) humanized
mice, a model validated to study HIV persistence. HIV
infected BLT mice were treated with tenofovir, emtricitabine and raltegravir. Despite documented tissue penetration by these drugs, we found that HIV expression persists
in cells isolated from all the tissues analyzed (bone
marrow, thymus, spleen, lymph nodes, liver, lung, intestines and peripheral blood cells). We therefore complemented ART with an immunotoxin that specifically kills HIV
expressing cells while leaving other cells untouched. Our
results demonstrate a dramatic reduction in persistent HIV
throughout the body resulting from the killing of virus
producing cells. Thus, our study provides new insights into
the locations of HIV persistence during ART and a
demonstration that persistent HIV can be successfully
targeted inside the body.
organs over time – a study that cannot be performed in human
subjects. For this reason, we used BLT humanized mice [24], the
most advanced, validated, and robust small animal model
available for this purpose [25,26]. The process of bioengineering
BLT mice results in systemic dissemination of human hematopoietic cells throughout the animal [24,27]. This phenotype facilitates
the simultaneous analysis of multiple tissues throughout the body.
The systemic effects of HIV infection on the BLT mouse human
immune system (e.g., CD4+ T cell depletion and immune
activation) recapitulate what is observed in HIV-infected patients
[28–32]. Once the tissue-specific parameters of HIV persistence
during ART were established, we incorporated 3B3-PE38 into the
therapeutic regimen. Systemic analyses revealed that 3B3-PE38
treatment during ART reduced the number of HIV RNA
producing cells to levels significantly lower than those achieved
with ART alone. This observation demonstrates that immunotoxins can play a critical role in successful HIV eradication
strategies.

Results
Outcomes of ART in HIV infected BLT mice
For this study, BLT mice were treated with a triple combination
antiretroviral drug regimen that included the nucleotide reverse
transcriptase inhibitor tenofovir disoproxil fumarate (TDF), the
nucleoside reverse transcriptase inhibitor emtricitabine (FTC) and
the integrase inhibitor raltegravir (RAL). This ART regimen was
chosen because of its robust pharmacodynamic properties [33],
superior efficacy in humans [34] and its efficacy in BLT mice [35].
In human peripheral blood [36,37] and BLT mice (Fig. 1A), the
first few weeks of ART are characterized by a rapid decline in
plasma viremia (vRNA) followed by a plateau phase concomitant
with a recovery of peripheral blood CD4+ T cells levels (Fig. 1B).
We also observed that the blood cell-associated vDNA levels
remained stable when compared to plasma vRNA levels during
this treatment period (Fig. 1A) (Day 23 vs. Day42, p = 0.63,
signed rank test), as seen in patients on this same ART regimen
PLOS Pathogens | www.plospathogens.org

Impact of HIV-specific immunotoxin on residual vRNA
production during ART
Since neither cytopathic effects of HIV expression or antiviral
immune responses are sufficient to deplete cells expressing virus [6],
these cells represent potential targets for cytotoxic HIV-specific
immunotherapies such as the immunotoxin 3B3-PE38. This
immunotoxin has been shown to be active against HIV-1-infected
2
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Figure 1. Efficacious plasma and tissue drug concentrations indicate broad dissemination of antiretrovirals during ART. (A) ART
suppressed plasma viremia to below detection (vRNA; solid line, closed symbols) while peripheral blood cell-associated vDNA (dashed line; open
symbols) were unaffected (Day 23 vs. Day42, p = 0.63, signed rank test). (B) ART led to a rebound in peripheral blood CD4+ T cells to pre-infection
levels. (C–E) Drug concentrations [tenofovir (C), emtricitabine (D) or raltegravir (E)] were determined within the plasma and each of the indicated
tissues. For this steady state drug concentration analysis, the 4 BLT mice in (A) were harvested 21 hours following their last ART dosing and the tissue
concentrations of the antiretrovirals were determined.
doi:10.1371/journal.ppat.1003872.g001

Figure 2. Durable reduction of the number of vRNA+ cells occurs during ART. Quantitative ISH analysis reveals statistically significant
reductions in the numbers of productively infected cells for each tissue obtained from animals undergoing antiretroviral therapy. Exact log rank tests
were utilized to generate p values. When no RNA+ cells were detected, then the number of RNA producing cells per gram tissue was set to 200 in the
graph. (Closed symbols = no ART; open symbols = ART).
doi:10.1371/journal.ppat.1003872.g002

PLOS Pathogens | www.plospathogens.org
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Figure 3. Viral RNA production during ART rapidly declines and then enters a plateau phase in all tissues. (A) Each data point indicates
cell-associated vRNA levels (y-axis) and the days following ART initiation (x-axis) for a given BLT mouse in the indicated tissues. Both Lowess (dashed
line) and a cubic (solid line) regression models were fit to the data for each tissue. (B) To facilitate comparative analyses between tissues, all of the
Lowess regressions are graphed together. (C) To determine the overall impact of ART on systemic cell-associated vRNA levels, data from all of the
tissues was used to generate a single Lowess curve.
doi:10.1371/journal.ppat.1003872.g003

primary CD4+ T cells, macrophages and thymocytes [43,44].
Knowing that the effect of ART on the vRNA production reached a
plateau by Day 28 of treatment led us to ask whether targeted killing
of the persisting HIV producing cells during this plateau phase
would augment the vRNA decline during ART [8]. As with most
anti-HIV agents, monotherapy with immunotoxins is not clinically
viable [8]; therefore, we quantitated the systemic impact of 3B3PE38 on HIV persistence during ART (7 IP doses on alternate days
beginning on Day 28 of ART). Compared to ART alone, ART plus
3B3-PE38 reduced the cell-associated vRNA by 3.2 logs (.1,000fold) in the bone marrow (Fig. 5A). Complementing ART with 3B3PE38 also led to a reduction in the persisting cell-associated vRNA
levels in the human thymic organoid, spleen, lymph nodes, liver
lung, intestines and peripheral blood cells (range: 0.4 to 1.5 logs)
(Fig. 5A). When all tissues were analyzed together, ART plus
PLOS Pathogens | www.plospathogens.org

3B3-PE38 reduced cell-associated vRNA levels in all organs
combined by an additional 0.8 logs compared to ART alone
(p,0.001) (Fig. 5B).
Following the initiation of ART in humans, there is a multiphasic decay in viremia that reflects the rate of turnover of
productively infected cells [36,45]. Most models of viral dynamics
assume that the drugs completely block new infections of
susceptible cells, with the observed decay reflecting the decay rate
of cells infected prior to the initiation of ART [36,46]. Because this
decay is constantly progressing, it is likely that the number of
vRNA producing cells would decline over time during ART in the
absence of immunotoxin treatment. However, given that we
observed an overall 0.8 log reduction in cell-associated vRNA
levels beyond the effect of ART alone (Fig. 5B), we used in situ
hybridization to examine whether there was an associated
4
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Figure 4. Each tissue analyzed exhibited a significant decline in vRNA during ART. When cell-associated vRNA levels during the plateau
stage (treated 28–64 days) are compared to those from untreated mice, the reduction in vRNA levels were significant in all tissues (p,0.001).
Reductions in cell-associated vRNA levels are presented as log10 differences in medians. Mann-Whitney tests were used to generate p values. (Closed
symbols = no ART; open symbols = ART).
doi:10.1371/journal.ppat.1003872.g004

reduction in the number of cells producing vRNA. We found that
complementation of ART with 3B3-PE38 led to a 1.8 log
reduction in the numbers of vRNA producing cells throughout the
body (p = 0.007) (Fig. 5C). This profound reduction in the number
of vRNA producing cells provides a mechanistic explanation for
the rapid reduction in tissue cell-associated vRNA levels relative to
the ART only experimental group.

Horwitz, et al. study, the amount of IgG (10.5 mg/injection)
administered was over 2000 fold higher than our doses of 3B3PE38 (0.005 mg/injection). Thus, the circulating 3B3-PE38 levels
in our study could not reach the levels required for neutralization
by 3B3 [48]. It is therefore unlikely under our experimental
conditions that neutralization by the 3B3 scFv moiety of the
immunotoxin accounts for the significant 3B3-PE38-mediated
reduction we observed in tissue cell-associated vRNA levels.
Comparing and contrasting data from BLT mice with data from
patients and NHP is essential to understanding the predictive
nature of our model. The most notable difference between our
study and those in patients and NHP is the duration of ART. Our
study examined the impact of ART in BLT mice over ,2 months,
while patient and macaque studies have examined cell-associated
vRNA levels during several years of ART [49,50]. These
differences in ART duration prevent direct comparisons of the
impact of long-term ART on persistent vRNA production within
these experimental platforms. Despite this constraint, we can
compare data across all three experimental platforms for
consistency. For example, we found that our data showing the
continued presence vRNA in BLT mouse peripheral blood and
tissue cells during ART are consistent with the continued presence
of vRNA within patient peripheral blood cells, ileal biopsy cells
and rectal biopsy cells from patients treated for a median of 12.5
months with ART [50] and within macaque cells from throughout
the body after 26 weeks on ART [49]. In addition to future studies
incorporating longer treatment windows in BLT mice, it will be
important to determine whether the vRNA plateau phase reached
after 28 days is directly comparable to that seen in humans on long
term ART. For this purpose, incorporation of an additional drug
into the ART regimen could be tested. If the plateau state in BLT
mice is comparable to the human situation during long-term ART,
then future studies using more sensitive assay for HIV-1 RNA in
conjunction with ART intensification should not detect any
additional reduction in the steady state level of viremia during this
timeframe.
The results presented here provide proof of concept for targeted
cytotoxic therapy as a successful complement to ART for the

Discussion
Despite the lifesaving benefits of ART in HIV patients,
relatively little is known regarding the organ specific impact of
this therapy on HIV production and persistence [23]. Improving
our knowledge of the systemic effects of ART is a critical step in
the development of successful HIV eradication therapies. To
address this need, we characterized the impact of ART by
analyzing both drug penetration and HIV production in different
tissues throughout BLT humanized mice. We found that ART
penetration into multiple organ systems is sufficient to significantly
reduce the number of cells producing HIV, as well as cellassociated vRNA levels, throughout the body. However, HIV
persists during ART in every organ analyzed.
HIV-infected cells persisting during ART represent suitable
targets for cytotoxic HIV-specific immunotherapies such as the
3B3-PE38 immunotoxin. Since such therapies target HIV proteins
expressed by infected cells, their efficacy requires active virus
transcription. Therefore there is no predicted impact of immunotoxin treatment on the size of the transcriptionally silent latent
HIV reservoir. For this reason, the HIV latent reservoir was not
quantitated in this study and our conclusions are based on the
quantitation of cell-associated vRNA and vRNA-producing cell
numbers. Specifically, we demonstrate that 3B3-PE38 kills vRNA
producing cells throughout the body such that the reduction of
vRNA levels during combined therapy is more rapid than with
ART only (Fig. 6). A recent report described the ability of new
broadly neutralizing monoclonal antibodies to suppress HIV-1
rebound after termination of ART [47] which led us to consider
the possibility that the observed activity of the immunotoxin was
due in part to neutralization by the 3B3 scFv moiety. In the
PLOS Pathogens | www.plospathogens.org
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Figure 5. 3B3-PE38 targets and systemically depletes vRNA+ cells in vivo. Beginning on Day 28 after ART initiation 3B3-PE38 was added to
the treatment regimen every other day (7 total doses: 4 at 1 mg/25 g followed by 3 at 5 mg/25 g). The ART only control includes mice treated for 28–
64 days. (A) Reductions in cell-associated vRNA levels are presented as log10 differences in medians. Mann-Whitney tests were used to generate p
values. (B) Reductions in cell-associated vRNA levels for all tissues in (A) are graphed alongside data from untreated mice (Wilcoxon rank-sum
statistics with repeated measures corrections). (C) Quantitative ISH for No ART mice (Fig. 2), ART only mice (Fig. 2) and the ART+3B3-PE38 group
revealed reductions in the total number of HIV RNA producing cells per gram. When no RNA+ cells were detected, then the number of RNA producing
cells per gram tissue was set to 200 in the graph (Exact log rank tests with repeated measures corrections).
doi:10.1371/journal.ppat.1003872.g005

selection of viral mutants resistant to any single immunotoxin [53].
Beyond immunotoxins, alternative targeted cytotoxic therapy
strategies developed for cancer treatment could also be adapted
to generate comprehensive anti-HIV cytotoxic therapy regimens
[54,55]. Possibilities include: aptamer—toxin conjugates; radioimmunotherapies; antibody—cytotoxic drug conjugates; targeted
cytolytic viruses; targeted delivery of a cytotoxic peptides; and
adoptive immunotherapy with ex vivo expanded natural or

depletion of persisting HIV infected cells. In addition to the 3B3PE38, alternative immunotoxins with different effector domains
and targeting moieties are available [8–10]. This is important
because: (i) treatments with different cytotoxic interventions during
ART will likely be required to completely eradicate HIV
producing cells due to the immunogenicity of the immunotoxin
molecules [8–13,51,52], the need to target the diverse cell types
that are productively infected with HIV [2–4], and (iii) the likely

PLOS Pathogens | www.plospathogens.org
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Figure 6. The 3B3-PE38 mediated killing of vRNA producing cells leads to a more rapid reduction in vRNA levels versus ART only.
The single Lowess curve for all data points in Fig. 3C (closed symbols; solid line) is graphed together with the combined tissue data for ART+3B3-PE38
(open symbols; dashed line) to reveal the alteration in cell-associated vRNA levels over time due to the immunotoxin. The beginning of the plateau
phase of decay (Day 28) is the divergence point.
doi:10.1371/journal.ppat.1003872.g006

reconstitution in peripheral blood by flow cytometry
[24,27,32,35]. All BLT mice (n = 40) used for these experiments
were characterized for human immune system reconstitution prior
to HIV infection. Their peripheral blood contained an average of
57% (+/215 SD) human CD45+ cells of which 58% (+/222 SD)
were human T cells. Of the human T cells, 81% (+/26 SD) were
human CD4+ T cells.

genetically modified T cells [54,55]. Importantly, the model
system developed herein to quantitate the effects of 3B3-PE38 can
be used to determine the in vivo efficacy of any of these other
strategies alone or in combinations.
In summary, we determined that the systemic penetration of
antiretroviral drugs into different organs throughout the body was
sufficient to reduce cell-associated vRNA levels ART alone was
unable to completely eliminate vRNA expressing cells in tissues.
This observation provided a quantitative framework for the
systemic in vivo efficacy evaluation of interventions to destroy HIV
producing cells during therapy. Within this framework we were
able to demonstrate that persistent HIV producing cells systemically present during ART were significantly depleted by an Envtargeting immunotoxin. Such targeted cytotoxic interventions may
prove to be critically important components of an effective HIV
eradication strategy.

Analysis of HIV infection of BLT mice
Infection of BLT mice with HIV-1JRCSF was monitored in
peripheral blood by determining plasma levels of vRNA as
described (level of detection = 750 copies per mL of plasma; 40 ml
mouse plasma sample size) using one-step reverse transcriptase
real-time PCR [ABI custom TaqMan Assays-by-Design] [35,56–
58]. Tissues were harvested and cells isolated as we have
previously described for RNA isolation or flow cytometric analysis
[24,32]. Flow cytometry data were collected using a BD
FACSCanto cytometer and analyzed using BD FACSDiva
software (v. 6.1.3).
For HIV RNA in situ hybridization (ISH), tissues were fixed
overnight in 4% paraformaldehyde at 4uC and then transferred to
70% ethanol. Tissues were then embedded in paraffin for
sectioning. After deparaffinization with xylene and rehydration
through graded ethanols, tissue sections were treated with HCl,
triethanolamine, digitonin and 4 mg/mL Proteinase K as previously described [59]. After acetylation with acetic anhydride and
dehydration, tissue sections were hybridized at 45uC overnight
with a 35S labeled antisense riboprobe and 0.5 mM aurintricarboxylic acid in the hybridization mix. After extensive washes and
ribonuclease treatment, tissue sections were dehydrated, coated in
Ilford K5 emulsion diluted with glycerol and ammonium acetate,
exposed at 4uC for 7–14 days, and developed and fixed per
manufacturer’s instructions. They were stained with Hematoxylin,

Materials and Methods
Ethics statement
All animal experiments were conducted following NIH guidelines for housing and care of laboratory animals and in accordance
with The University of North Carolina at Chapel Hill (UNC
Chapel Hill) regulations after review and approval by the UNC
Chapel Hill Institutional Animal Care and Use Committee (permit
number 12-171).

Generation of BLT humanized mice
BLT mice were prepared essentially as previously described
[27]. Briefly, thy/liv implanted NOD/SCID-gamma chain null
mice (NSG; The Jackson Laboratories, Stock #5557) were
transplanted with autologous human fetal liver CD34+ cells
(Advanced Bioscience Resources) and monitored for human
PLOS Pathogens | www.plospathogens.org
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trile containing isotopically-labeled internal standards (13C TFV,
and 13C 15N FTC). Following vortexing and centrifugation, the
supernatant was removed and evaporated to dryness. The extracts
were reconstituted with 1 mM ammonium phosphate prior to LCMS/MS analysis. TFV and FTC were eluted from a Waters
Atlantis T3 (10062.1 mm, 3 mm particle size) analytical column.
RAL was eluted from a Phenomenex Synergi Polar-RP
(5064.6 mm, 4 mm particle size) analytical column. An API5000 triple quadrupole mass spectrometer was used to detect all
analytes. Data were collected using AB Sciex Analyst Chromatography Software. The dynamic range of this assay was 0.3–
300 ng/mL of homogenate for each compound using a 1/
concentration2 weighted linear regression. Based upon the mass of
the tissue extracted, the concentrations were converted from ng/
mL homogenate to ng/g tissue. Calibrators and quality control
samples were within 15% of the nominal value all compounds.

dehydrated, and mounted with Permount. Non-infected control
tissues and sense riboprobe controls were analyzed when
appropriate. Photographic images using epifluorescence were
taken with a digital camera and the tiffs were analyzed for the
area of the sections and the area occupied by silver grains using
Photoshop with Fovea Pro. Section weights were estimated from
their 5-micron thickness and their area. These methods have been
extensively reviewed [59].

Treatment of HIV infection of BLT mice
ART in infected BLT mice consisted of three antiretrovirals
administered daily via intraperitoneal injection: tenofovir disoproxil fumarate (TDF; 208 mg/kg), emtricitabine (FTC;
240 mg/kg body weight) and raltegravir (RAL; 56 mg/kg) [35].
The gp120-targeting immunotoxin 3B3(Fv)-PE38 [22] (here
referred to as 3B3-PE38) was administered intraperitoneally every
other day beginning on Day 28 of ART for a total of 7 doses: the
first 4 were 1 mg/25 g and the last 3 were 5 mg/25 g.

Statistics
All statistical tests performed using an alpha level of 0.05. Exact
log rank tests were utilized to generate p values for Fig. 2 (R
v2.14.1). Mann-Whitney comparisons were utilized to generate
the p values presented in Figs. 4 & 5A (Prism v4). Wilcoxon ranksum statistics with repeated measures corrections were utilized to
generate p values presented in Fig. 5B (R). Exact log rank tests
with repeated measures corrections were utilized to generate p
values for Fig. 5C (R). For Figs. 3 & 6, the Lowess and cubic
regression models were fit using R. The linear heterogeneity
models that allowed for the residual variance to change over time
were computed in SAS/STAT software. Graphs were generated
in Prism v4 with the exception of the fitted Lowess and cubic
regression models which were generated in R.

Analytical methods for drug quantification
Plasma and snap frozen tissue samples from BLT mice receiving
daily ART were analyzed for drug concentrations. Quantification
of FTC, tenofovir (TFV) and RAL plasma concentrations was
performed by protein precipitation and LC-MS/MS analysis.
10 ml of each stored plasma sample was mixed with 75 mL of
methanol containing the isotopically-labeled internal standards
(13C TFV and 13C 15N FTC). Following vortexing and centrifugation, the supernatant was removed and evaporated to dryness.
The extracts were reconstituted with 1 mM ammonium phosphate
prior to LC-MS/MS analysis. All compounds were eluted from a
Phenomenex Synergi Polar-RP (4.6650 mm, 4 mm particle size)
analytical column. An API-5000 triple quadrupole mass spectrometer (AB Sciex, Foster City, CA) was used to detect the
analytes. Data were collected using AB Sciex Analyst Chromatography Software (Analyst version 1.6.1). The dynamic range of
this assay was 1–1000 ng/mL for each compound using a 1/
concentration2 weighted linear regression. Calibrators and quality
control samples were within 15% of the nominal value for all
compounds. Plasma samples with concentrations above the
calibration range were diluted into the calibration range with
blank plasma prior to reanalysis.
The quantitation of FTC, TFV and RAL in tissues started with
the homogenization of each tissue in a 70% acetonitrile + 30%
1 mM ammonium phosphate solution. A portion of the resulting
homogenate was extracted by protein precipitation with acetoni-
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